The global Somatropin market is studied in detail in the new report on Qualiket Research. The new report studies the Somatropin market by profiling its major driving factors and restraining factors, compiling a comprehensive database on the market’s historical growth trajectory and present conditions, and by using easy formulation of calculations and estimations through the use of industry-leading analytical tools and methods. The key economic factors affecting the global Somatropin market are studied in detail in the global Somatropin market report, including a detailed assessment of the microeconomic and macroeconomic environment of the market.
Request Sample Copy of this Report @ https://qualiketresearch.com/request-sample/Somatropin-Market/request-sample
Somatropin is a human growth hormone indicated for the treatment of growth hormone deficiency in adults and children. Also, it is used for treatment of Prader-Willi syndrome, Chronic Renal Insufficiency, Turner syndrome Turner syndrome, and others. Somatropin stimulates tissue growth, and protein, lipid, carbohydrates and mineral metabolism in the body.
Rise in approvals of somatropin products by regulatory authorities such as USFDA (Food and Drug Administration) is the key driving factor which is expected to boost the global somatropin market growth. For instance, in July 2018, U.S. Food and Drug Administration had approved ZOMACTON, a Somatropin injection of Ferring Pharmaceuticals Inc, for additional pediatric indications such as Idiopathic short stature (ISS), Growth failure in short stature homeobox-containing gene (SHOX) deficiency, Short stature born small for gestational age (SGA) with no catch-up growth by 2 to 4 years, and Short stature due to Turner syndrome. Furthermore, increase in prevalence of growth hormobe deficiency in children will positively contribute the market growth over the forecast period. As per article published in the Springer Nature Journal in Feb 2017, the prevalence of GHD (Growth Hormone Deficiency) in children is within range 1.8 -2.9 per 10,000 children in Europe and the U.S.
However, key manufacturers are focused on developing advanced alternative treatments for growth hormone deficiency is the major challenging factor which is expected to hinder the global somatropin market growth. For instance, in October 2019, OPKO Health and Pfizer had announced the results of Phase III clinical trials, which was initiated to evaluate the efficacy and safety of somatrogen, which is long acting human growth hormone molecule administrated once in a week for growth hormone deficiency.
Market Key Players
Various key players are discussed in this report such as Novo Nordisk A/S, Eli Lilly and Company, Pfizer, Inc., GeneScience Pharmaceuticals, Ipsen Inc.,Sandoz International, LG Life Sciences, Merck, Hoffmann-La Roche, and Teva Pharmaceuticals.
By Dosage Form
- Growth Hormone Deficiency (GHD)
- Turner Syndrome
- Chronic Rental Insufficiency
- Prader Willi Syndrome
- SHOX Deficiency
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East & Africa
Browse Full Research Report @ https://qualiketresearch.com/reports-details/Somatropin-Market
QualiKet Research is a leading Market Research and Competitive Intelligence partner helping leaders across the world to develop robust strategy and stay ahead for evolution by providing actionable insights about ever changing market scenario, competition and customers. QualiKet Research is dedicated to enhancing the ability of faster decision making by providing timely and scalable intelligence. We use different intelligence tools to come up with evidence that showcases the threats and opportunities which helps our clients outperform their competition.
Research Support Specialist
6060 N Central Expy #500, TX 75204, U.S.A